INCLINE VILLAGE, Nev. , March 1, 2018 /PRNewswire/ -- PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today announced that the Company will release its fourth quarter, year-end 2017 financial results for the period ended December 31, 2017 , on Thursday March 8, 2018 , after market close.
INCLINE VILLAGE, Nev. , Feb. 14, 2018 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin , PDL's chief executive officer, will present at the following two upcoming investor conferences: 2018 RBC Capital Markets Global Healthcare Conference Wednesday
INCLINE VILLAGE, Nev. , Nov. 8, 2017 /PRNewswire/ -- PDL BioPharma, Inc. (NASDAQ: PDLI) reiterated that its proposal to acquire Neos Therapeutics, Inc. (NASDAQ: NEOS) for $10.25 per share in cash will expire today at market close. PDL originally made public its proposal to acquire Neos on October
INCLINE VILLAGE, Nev. , Nov. 7, 2017 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin , PDL's president and chief executive officer, will present at two investor conferences in November. Jefferies 2017 London Healthcare Conference Wednesday,
INCLINE VILLAGE, Nev. , Oct. 30, 2017 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (NASDAQ: PDLI) today issued the following statement in response to the Neos Therapeutics, Inc. ("Neos") (NASDAQ: NEOS) Board of Directors' rejection of PDL's October 26 proposal to acquire Neos for
INCLINE VILLAGE, Nevada , Oct. 30, 2017 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (NASDAQ: PDLI) today announced that on October 27, 2017 , PDL and Depomed, Inc. ("Depomed") entered into a settlement agreement with Valeant Pharmaceuticals International, Inc.
- Proposal provides immediate and certain value to Neos shareholders - Proposal represents a 40% premium to Neos' October 25 closing price and provides shareholders a substantial premium - Supports PDL's specialty pharmaceutical acquisition strategy
INCLINE VILLAGE, Nev. , Oct. 25, 2017 /PRNewswire/ -- PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today announced that the Company will release its third quarter financial results for the period ended September 30, 2017 , on Thursday, November 2, 2017 , after market close.
INCLINE VILLAGE, Nev. , Sept. 25, 2017 /PRNewswire/ -- PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) announced today that PDL's board of directors has authorized a new stock repurchase program to acquire up to $25 million of the Company's common stock. Purchases may be made in
INCLINE VILLAGE, Nev. , Sept. 19, 2017 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin , PDL's chief executive officer, will present at the 2017 Cantor Fitzgerald Global Healthcare Conference in New York City on Tuesday, September 26, 2017 , at
INCLINE VILLAGE, Nev. , Sept. 11, 2017 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the company has appointed Dominique P. Monnet to the position of president. Mr. Monnet brings over 30 years of international business experience in the biotechnology /
INCLINE VILLAGE, Nev. , Sept. 6, 2017 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin , PDL's president and chief executive officer, will present at two investor conferences in September. Rodman & Renshaw 19 th Annual Global Investment Conference
